Imago BioSciences, Inc. (NASDAQ:IMGO - Get Rating) - Equities researchers at Wedbush issued their Q2 2023 earnings per share (EPS) estimates for Imago BioSciences in a report issued on Monday, November 21st. Wedbush analyst R. Driscoll forecasts that the company will post earnings per share of ($0.63) for the quarter. Wedbush currently has a "Neutral" rating and a $36.00 price target on the stock. The consensus estimate for Imago BioSciences' current full-year earnings is ($1.93) per share. Wedbush also issued estimates for Imago BioSciences' Q3 2023 earnings at ($0.61) EPS and Q4 2023 earnings at ($0.65) EPS.
A number of other research analysts also recently weighed in on IMGO. Cowen downgraded Imago BioSciences to a "market perform" rating and set a $36.00 target price on the stock. in a report on Tuesday. HC Wainwright downgraded Imago BioSciences from a "buy" rating to a "neutral" rating and increased their target price for the company from $35.00 to $36.00 in a report on Tuesday. Jefferies Financial Group downgraded Imago BioSciences from a "buy" rating to a "hold" rating and increased their target price for the company from $35.00 to $36.00 in a report on Monday. Finally, Cowen downgraded Imago BioSciences from an "outperform" rating to a "market perform" rating and set a $36.00 target price on the stock. in a report on Monday. Five analysts have rated the stock with a hold rating, According to MarketBeat, the stock presently has an average rating of "Hold" and an average price target of $36.00.
Imago BioSciences Stock Up 0.1 %
Imago BioSciences stock opened at $35.64 on Thursday. Imago BioSciences has a one year low of $11.56 and a one year high of $35.75. The business's fifty day moving average is $17.28 and its 200 day moving average is $16.10.
Institutional Inflows and Outflows
Several institutional investors have recently made changes to their positions in the stock. Ameritas Investment Partners Inc. raised its stake in shares of Imago BioSciences by 108.3% in the first quarter. Ameritas Investment Partners Inc. now owns 1,556 shares of the company's stock worth $30,000 after buying an additional 809 shares during the period. Metropolitan Life Insurance Co NY bought a new position in shares of Imago BioSciences in the first quarter worth about $28,000. Legal & General Group Plc raised its stake in shares of Imago BioSciences by 46.2% in the second quarter. Legal & General Group Plc now owns 6,098 shares of the company's stock worth $81,000 after buying an additional 1,926 shares during the period. Swiss National Bank raised its stake in shares of Imago BioSciences by 7.8% in the first quarter. Swiss National Bank now owns 27,800 shares of the company's stock worth $536,000 after buying an additional 2,000 shares during the period. Finally, Amalgamated Bank bought a new position in shares of Imago BioSciences in the first quarter worth about $41,000. Institutional investors own 99.50% of the company's stock.
About Imago BioSciences
Imago BioSciences, Inc, a clinical stage biopharmaceutical company, discovers and develops small molecule product candidates that target lysine-specific demethylase 1(LSD1), an enzyme that used in the production of blood cells in the bone marrow. Its lead product candidate is bomedemstat, which is in Phase II clinical trials for the treatment of myeloproliferative neoplasms chronic cancers of the bone marrow, such as myelofibrosis, essential thrombocythemia, and polycythemia vera.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to email@example.com.
Before you consider Imago BioSciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Imago BioSciences wasn't on the list.
While Imago BioSciences currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here